Département Universitaire de Radiothérapie, CyberKnife Nord-Ouest, Centre Oscar Lambret, CLCC, Université Lille II, Lille, France.
Radiat Oncol. 2011 Jun 23;6:77. doi: 10.1186/1748-717X-6-77.
The first-line treatment of a pelvic recurrence in a previously irradiated area is surgery. Unfortunately, few patients are deemed operable, often due to the location of the recurrence, usually too close to the iliac vessels, or the associated surgical morbidity. The objective of this study is to test the viability of robotic image-guided radiotherapy as an alternative treatment in inoperable cases.
Sixteen patients previously treated with radiotherapy were reirradiated with CyberKnife® for lateral pelvic lesions. Recurrences of primary rectal cancer (4 patients), anal canal (6), uterine cervix cancer (4), endometrial cancer (1), and bladder carcinoma (1) were treated. The median dose of the previous treatment was 45 Gy (EqD2 range: 20 to 96 Gy). A total dose of 36 Gy in six fractions was delivered with the CyberKnife over three weeks. The responses were evaluated according to RECIST criteria.
Median follow-up was 10.6 months (1.9 to 20.5 months). The actuarial local control rate was 51.4% at one year. Median disease-free survival was 8.3 months after CyberKnife treatment. The actuarial one-year survival rate was 46%. Acute tolerance was limited to digestive grade 1 and 2 toxicities.
Robotic stereotactic radiotherapy can offer a short and well-tolerated treatment for lateral pelvic recurrences in previously irradiated areas in patients otherwise not treatable. Efficacy and toxicity need to be evaluated over the long term, but initial results are encouraging.
在先前照射区域发生骨盆复发时,一线治疗方法是手术。遗憾的是,由于复发部位通常靠近髂血管,或相关手术发病率较高,仅有少数患者被认为适合手术。本研究旨在测试机器人图像引导放疗在不可手术病例中作为替代治疗的可行性。
16 例先前接受过放疗的患者接受 CyberKnife®治疗侧骨盆病变。治疗的复发性疾病包括原发性直肠肿瘤(4 例)、肛管(6 例)、子宫颈癌(4 例)、子宫内膜癌(1 例)和膀胱癌(1 例)。先前治疗的中位剂量为 45 Gy(EqD2 范围:20 至 96 Gy)。使用 CyberKnife 在三周内分六次给予 36 Gy 的总剂量。根据 RECIST 标准评估反应。
中位随访时间为 10.6 个月(1.9 至 20.5 个月)。一年时的局部控制率的 actuarial 为 51.4%。CyberKnife 治疗后无疾病进展生存时间的中位数为 8.3 个月。一年时的 actuarial 生存率为 46%。急性耐受仅限于消化 1 级和 2 级毒性。
机器人立体定向放疗可为先前照射区域内侧骨盆复发的患者提供一种短期且耐受性良好的治疗方法,这些患者否则无法治疗。需要长期评估疗效和毒性,但初步结果令人鼓舞。